If you want to  participate as investor, click here.



Meet the participating venture capital funds


Samuel Shafner is a US-based business, finance and securities lawyer serving clients based in Western Europe and the US.  For the past 15 years, Samuel was Chairman of the International Practice Group at a regional law firm in Boston.  Then in 2015 he moved to FisherBroyles, a larger law firm with offices throughout the US.  FisherBroyles has exceptionally low overhead, enabling its partners to charge very low hourly rates, even though its practice is international in scope and sophistication.  His expertise is focused upon venture capital, mergers and acquisitions, and domestic and international business law. Samuel counsels international clients in both routine and extraordinary business transactions, especially those potentially involving US parties or investors. He often helps start-ups pitch venture and strategic investors, including US and European investor contacts of his own.  He frequently advises on strategic partnerships and investments, acquisitions and divestitures, securities law, corporate governance, and other business and transactional matters. He is best known for his work with helping young enterprises to launch well, scale smoothly and exit profitably.  Besides advising venture capital funds, Samuel also assists large international public companies in structuring and operating successful strategic venture capital divisions to monitor potentially game-changing developments within their business sectors.

Life Sciences


Name Fund: Flare Capital  / www.flarecapital.com

Name Contact Visit: Michael Greeley



Michael is a General Partner at Flare Capital Partners. Prior to co-founding Flare Capital Partners, Michael was a founding General Partner of Flybridge Capital Partners where he led the firm’s healthcare investments. He also served on the board of International Data Group, the initial flagship Limited Partner for the IDG Ventures global network of funds and Flybridge Capital Partners.

Current and prior board seats include BlueTarp Financial, Explorys, Functional Neuromodulation, Iora Health, MicroCHIPS, Nuvesse, PolyRemedy, Predictive Biosciences, Predilytics, T2 Biosystems, TARIS Biomedical, VidSys and Welltok.

Previously, Michael focused on emerging-growth company financings with Polaris Venture Partners, was a senior vice president and founding partner of GCC Investments, and held positions at Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston.

Michael currently serves as chairman of the Entrepreneurship Committee of the Massachusetts Information Collaborative and on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. Michael also serves on the Industry Advisory Board of the Cleveland Clinic, as well as serving on several other boards including the New England Investors’ Committee of Capital Innovation. He was the former chairman of the New England Venture Capital Association and on the Executive Committee of the board of the National Venture Capital Association. Named by the Boston Globe as the “Go-To” investor for life sciences, healthcare and medical devices and a Mass High Tech All-Star, Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School.

Flare Capital


Flare Capital Partners, formerly known as Foundation Medical Partners, is the venture capital arm of Cleveland Clinic Foundation specializing in growth equity, early stage, and seed/startup investments. It typically invests in healthcare technology. The firm also seeks to invest in life science and healthcare with a special interest in medical devices, medical device research equipment, biopharmaceutical platforms and products, and other opportunities in health care including diagnostics, predictive medicine technology and services, data-centric devices, healthcare industry software, health care services, and health care information systems and digital health technology companies. The firm focuses on transformational technologies and services that enable value-based healthcare and leverage mobile-based 24/7 solutions, big data and analytics technologies. Flare Capital Partners was founded in 2001 and is based in Boston, Massachusetts with additional office in Rowayton, Connecticut.

Companies Investment:

Flare Capital Partners invests and specializes exclusively in the healthcare technology sector.

Working side-by-side, Flare Capital parlays strengths in business and medicine into action that supports entrepreneurs who provide innovative solutions and strive to be market leaders.

Companies Investment

Implantable pressure sensors for disease management


Diagnósticos móviles para arritmias cardiacas.

 Mobile diagnostics for cardiac arrhythmias.

Cuidado de la salud mediante cloud

 Healthcare cloud computing


 Percutaneous heart valve replacement technology.

Líder de la informática en la Salud.

 Healthcare informatic leader.

Sistema operativo de colaboración en atención de salud.

 Health care operating system for collaborative care.

Dispositivos medico para el tratamiento de la enfermedad de alzheimer.

 Medical for treating Alzheimer´s Disease.

Soluciones de datos y análisis para la prestación de asistencia eficiente.

 Data and analytics solutions for efficient healthcare delivery.

Tecnología de neuromodulación para tartar una variedad de enfermedades.

 Neuromodulation technology to treat a varietyof diseases.

Utilización de la informática para el diagnóstico de los trastornos del neurodesarrollo.

 Diagnostics and informatic for neurodevelopmental disorders.

Soluciones para empoderar la atención basada en el cuidado en la salud.

 Solutions to empower value-based care.

Análisis de datos predictivos de gestión de riesgos.

 Predictive data analytics for risk management.

Name Fund: Orbimed Israel Partners

Name Contact Visit: Nissim Darvish, M.D., Ph.D.

Senior Managing Director


Dr. Darvish is a Senior Managing Director at OrbiMed. Dr. Davish is a veteran of the life science industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Dr. Darvish spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Dr. Darvish was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Dr. Darvish obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received eight prizes and awards.

Orbimed Israel Partners


Orbimed Healthcare Fund Management, a New York-based investment management firm focused on health-care, started the Orbimed Israel Partners $222 million fund in Israel in April 2012 with partial government investment.

OrbiMed Israel Partners specializes in seed stage through growth equity investments. The fund seeks to invest in life sciences sector with a focus on biomedical, biotechnology, pharmaceutical, drug, diagnostics companies, and medical-device companies. It typically invests in Israel.

Name Fund: Clarus Ventures / www.clarusventures.com

Name Contact Visit: Scott Requadt, JD, MBA.

Managing Director


SCOTT REQUADT Managing Director Clarus Ventures Scott Requadt, JD, MBA, is currently a Managing Director for Clarus Ventures. Scott has 15+ years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. At TransForm, Scott had broad responsibility for business development, corporate development and legal activities, including managing the company’s intellectual property group. Prior to TransForm, Scott practiced for several years as an M&A attorney at the NYC-based law ‑rm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance)from McGill University (First Class Honors), a J.D. from University of Toronto and most recently an MBA from Harvard Business School, where he was a Baker Scholar. Mr. Requadt has been involved in multiple Clarus investments spanning both therapeutics and medtech. More recently, he led Clarus’ investments in a royalty interest in ibrutinib and in the IPO of Intercept Pharmaceuticals (NASDAQ:ICPT), and has been involved in several structured R&D risk-sharing investments with large pharma partners.

Clarus Ventures is a global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, we approach healthcare investing with a passion for novel ideas and the discipline to generate attractive and predictable returns. Clarus manages $1.7 billion of assets across three funds. Through multiple platforms we have invested in over 50 private and public companies in the biotechnology, medical device, and diagnostic spaces.

Our team’s expertise has enabled us to establish a long history of creating value through partnerships with Entrepreneurs, The Biopharmaceutical and Medical Technology industries to develop cutting edge therapeutics, devices and diagnostics. Our diverse network has allowed us to source and capitalize on unique investment opportunities.

In every investment we employ a hands-on philosophy and adhere to our investment principals which are founded on our core competencies of development and clinical expertise, regulatory knowledge, and the ability to adapt to an ever changing investment landscape. We strive to generate outstanding returns for our investors and thrive on discovering and developing innovative products that improve people’s lives.

Clarus Ventures


Orbimed Healthcare Fund Management, a New York-based investment management firm focused on health-care, started the Orbimed Israel Partners $222 million fund in Israel in April 2012 with partial government investment.

OrbiMed Israel Partners specializes in seed stage through growth equity investments. The fund seeks to invest in life sciences sector with a focus on biomedical, biotechnology, pharmaceutical, drug, diagnostics companies, and medical-device companies. It typically invests in Israel.

Name Fund: Omega Funds / http://www.omegafunds.net/

Name Contact Visit: Richard Lim.



Richard joined Omega Funds after over 16 years in principal investment and strategic consulting, all within life science and healthcare. He was previously a General Partner at MVM Life Science Partners, a life science focused venture capital firm with $500 million under management; he founded MVM’s US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), a private equity firm with $1.7bn under management, where he specialized in healthcare growth capital and leveraged transactions. Prior to SKM (now known as Apax Partners Inc.), Richard was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than 3 dozen small and large biotechnology firms. He was also an Associate with M&A investment bank BT Wolfensohn. He has served on a number of boards in biotechnology, specialty pharmaceuticals, and medical device companies. He serves on the advisory boards of the Deshpande Center at the Massachusetts Institute of Technology. He earned AB and MBA degrees from Harvard University.

Omega Funds

Founded in 2004, Omega Funds is a dedicated global life sciences investment firm headquartered in Boston, with additional operations in London and San Francisco.  Since its founding, the firm has raised $700M.  At its inception, the firm specialized in direct secondary transactions providing total or partial liquidity to investors unable to follow on their original investment.  Today, we are deploying Omega Fund V, a $300M fund investingdirectly in public and private companies, across all healthcare and life sciences sectors, including biotech, medical devices, diagnostics, services and healthcare IT.  We also continue to provide customized solutions for investors seeking partial or complete liquidity for their shareholdings.  Omega has a strong track record of identifying great management teams and companies and of backing them with capital, expertise and access to our network of relationships and resources, resulting in high-value exit outcomes.

Name Fund: Accuitive Medical Ventures / http://www.amvpartners.com/

Name Contact Visit: Tom Weldon

Managing Director


Thomas D. Weldon
Chairman, Managing Director

As a co-founder of Accuitive Medical Ventures, Tom brings over 25 years of operating experience, as well as critical fundraising skills in the medical device industry. Tom co-founded the medical device incubator The Innovation Factory (TIF) and serves as its chairman. He was also a co-founder and chairman of Novoste Corporation, the intracoronary radiation therapy company. He was chairman and CEO of Novoste from its inception in 1992 and led the company through its initial public offering in 1996.

Through his role at The Innovation Factory, Tom has co-founded numerous companies including: AcuFocus, AqueSys, Halscion, Liposonix, Neuronetics, and, Sebacia. He was formerly the chairman of LipoSonix, prior to its sale. Tom holds nearly two dozen issued U.S. patents on medical devices. Before co-founding Novoste, Tom held positions with Novoste Puerto Rico, Arthur Young & Company and Key Pharmaceuticals in various business and project management roles. Tom holds a B.S. in Industrial Engineering from Purdue University and an M.B.A. from Indiana University.

Tom currently serves as a board member for MyoScience, Respicardia, and Sebacia.

Accuitive Medical Ventures


Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. We have offices in Atlanta, GA and Amelia Island, FL. We are a market driven firm looking for revolutionary medical device technology investment opportunities.

Accuitive specializes in two distinct types of investments:

    • Venture financing for companies with outstanding technology and teams
    • Venture financing and management of technologies being developed within The Innovation Factory

Accuitive Medical Ventures has a strong relationship with The Innovation Factory (TIF), the successful medical technology serial operating team. TIF has started thirteen companies since 1999 and is based in Atlanta, GA. In conjunction with TIF, Accuitive Medical Ventures has the resources and experience to create long-term value for all medical technology stakeholders.

Accuitive has established relationships with some of the industry’s leading institutions to offer emerging companies and investors the opportunity to build unique new businesses and long-term shareholder value. Accuitive’s connections to some of the industry’s leading practitioners, thought leaders and venture capital firms enable us to add substantial value as investors and board members.

Cleantech/Energy Tech

Name Fund: CycleCapital / www.cyclecapital.com

Name Contact Visit: Shirley Speakman



Shirley Speakman joined Cycle Capital as a Partner and is based in our Toronto office. Shirley was the Director of Investments for the MaRS Investment Accelerator Fund (IAF) a $40M+ venture capital fund established by the Ontario government to invest in seed and early stage technology oriented companies based in Ontario. As Director of Investments, Shirley was responsible for investment recommendations and decisions, portfolio management, sourcing and partnering. Shirley continues to contribute to the MaRS Investment Accelerator Fund as an advisor on its cleantech investment committee. During her tenure at IAF, she oversaw investments in cleantech, successfully exited investments and assisted portfolio companies secure signficiant follow-on financing.

Prior to joining the IAF, Shirley spent over 12 years acting as advising biotech, ag-biotech and advanced manufacturing and materials companies in areas such as strategy, finance, negotiations and fund raising. She spearheaded numerous financings and M&A transactions and participated in the creation of a $40M cross border life sciences fund and the close of a Canadian based $40M ag-biotech fund.

Shirley holds her ICD.d (University of Toronto), a MBA from Wilfrid Laurier University and a Bachelor’s of Economics from the University of Waterloo.



Cycle Capital is a pioneer in Canadian Cleantech venture capital fund management investing in companies at the development and commercialization stages in North America. Founded in 2009 by Andrée-Lise Méthot, Founder and Managing Partner, Cycle Capital’s Platform has become an important venture capital investor of the Cleantech industry with its 3 funds totaling $230M Assets Under Management (AUM). Cycle Capital is looking to invests in promising ventures that are not capital intensive and/or that can benefit from the leverage brought by Cycle Capital extensive network of investors, strategic partners and advisors.

In addition to its core investments, Cycle Capital targets companies with high growth potential – especially those with strong intellectual property, leading edge technologies and with exceptional management talent that would benefit from the firm’s network of strategic industrial partners and expert advisors. With its core investment and business expertise, Cycle Capital plays an active role adding meaningful and tangible value to its portfolio companies at all stages of their life.

In order to effectively evaluate the potential of a technology and to contribute to its deployment, the Cycle Capital deal team utilizes a Value Chain Analysis process that identifies and evaluates multiple factors that will contribute to the venture’s success, including competition, partners, potential acquirers and business models. Other interrelated factors taken into consideration include intellectual property (IP) strategy, the sales cycle, government regulation and policy, compensation/incentive measures, etc. This analysis is a critical step in Cycle Capital extensive due diligence process and best investment practices. For Cycle Capital and its partners, the transformation of the global economic model to one of responsible production and consumption of resources and energy is driving the development of technologies and represents important investment opportunities.

Companies Investment

Agrisoma, desarrolla y vende semillas carinata Resonance® a los agricultores para la producción de aceite no alimentaria para la fabricación de combustibles sostenibles y renovables.

Agrisoma, develops and sells Resonance® carinata seeds to farmers for theproduction of non-food oil for the manufacture of sustaintable,renewable fuels.

Airex, Energy, desarrolla y comercializa tecnología para la biomasa basado en un reactor de lecho ciclónica patentada.

Airex, Energy, develops and sells technology for biomass torrefaction based on a unique patented cyclonic bed reactor.

CVT Corp, desarrolla y comercializa un nuevo toroidal de transmisión continua variable ( CVT ) para los generadores de energía y vehículos pesados de motor. Desarrollo sostenible: ahorro de costes de energía.

 CVT Corp is developing and commercializing a new troidal continuosly variable transmission (CVT) for power generators and heavy motor vehicles.Sustainable Developmente:Energy cost saving

Energate Inc. proporciona soluciones interactivas de gestión de energía.

Energate Inc. provides interactive energy managment solutions.

Enerkem, es una empresa líder de residuos en biocombustibles. Su tecnología termo-química patentada convierte materiales residuales, como los residuos sólidos urbanos no reciclables, en combustibles limpios para el transporte, los productos químicos renovables y la electricidad.

Enerkem, isa leading waste-to-biofuels company.Its proprietary thermo-chemical technology converts residual materials, such as non-recyclable municipal solid waste,into clean transportation fuels,renewable chemicals and electricity

EocycleTechnologies, ha desarrollado y comercializado un alternador de accionamiento directo para aerogeneradores. Desarrollo Sostenible : Mejora la fiabilidad de aerogeneradores (sin caja de cambios).

Eocycle Technologies, has developed and commercializes a direct drive alternator for wind turbines.Sustainable Development:Improves wind turbine reliability (no gear box).

GaN Systems , desarrollos para la próxima generación de energía nitruro de galio transistores de conmutación para una amplia variedad de mercados.

GaN Systems , GaN Systems markets and develops next generation gallium nitride power switching transistors for a wide variety of markets.

GreenMantra , produce ceras industriales sintéticos a partir de plásticos reciclados utilizando su tecnología patentada despolimerización catalítica.

GreenMantra , produces synthetic industrial waxes from recycled plastics using its patented catalytic depolymerisation technology .

Inocucor Technologies ,  desarrolla productos biológicos sostenibles para la fito-microbioma que son seguros para las personas, protege nuestros recursos naturales y aumenta el potencial de la agricultura para alimentar al mundo.

Inocucor Technologies ,develops sustainable biological products for the phyto-microbiome that are safe for people, protect our natural resources and increase agriculture’s potential to feed the world.

Laboratoire M2,  manufacturas de limpieza biodegradables y soluciones desinfectantes.

Laboratoire M2,manufactures biodegradable cleaning and disinfectant solutions.

LED Roadway Lighting (LRL), diseña y fabrica insumos para la calle y zona luminarias que tienen una esperanza de vida de 20 años y generan 60 % más de ahorro de energía que los accesorios que utilizan la tecnología existente.

LED Roadway Lighting (LRL),designs and manufactures street and area lighting fixtures that have a 20-year life expectancy and generate 60% more energy savings than fixtures using existing technology .

Lufa Farms ,  construye mundiales para fincas urbanas de efecto invernadero en la azotea para la producción agrícola.

Lufa Farms ,builds world first urban rooftop greenhouse farms for agricultural production.

MineSense, desarrolla sistemas de telemetría minerales basados en sensores para la base de gran escala y minas de metales preciosos para reducir unidad de energía y el uso del agua, al tiempo que aumenta la extracción de metales en general.

MineSense, develops sensor-based mineral telemetry systems for large-scale base and precious metal mines to reduce unit energy and water usage, while increasing overall metal extraction.

YWire Technologies, diseña, fabrica y vende la gestión del sistema de iluminación de edificios comerciales y el control.

YWire Technologies,designs, manufactures and sells commercial building lighting system management and control .

Name Fund: CycleCapital / http://www.pangaeaventures.com/

Name Contact Visit: Keith Gillard



Keith has been investing in cleantech and advanced materials start-up companies since 2001, initially with Mitsubishi Corporation, where he was responsible for technology-related investment and business development activities in Canada, with a specic focus on cleantech. From 2006-2010, Keith was President of BASF Venture Capital America Inc., establishing the Silicon Valley VC presence for the company. Keith began his career in investment banking before spending most of the 1990’s as an IT entrepreneur, establishing three companies in succession and taking them from business plan through financing to completion of product and exit. Keith is chairman of Vestaron Corporation and sits on the board of the Foresight Cleantech Accelerator Centre, with an active observer role at NewLeaf Symbiotics Inc. He is the co-author of “Inside the Minds: Energy Venture Capital Best Practices”, published in 2008 by Aspatore Books. He has a Bachelor of Arts from the University of British Columbia.

Pangaea Ventures


Pangaea Ventures is the world leader in advanced materials venture capital, investing in energy, electronics, health, and sustainability.  Established in 2000, Pangaea has offices in Vancouver Canada and New Jersey.  Pangaea’s Limited Partners include some of the world’s most successful materials companies: Asahi Glass, Asahi Kasei, BASF, Bekaert, Castrol innoVentures, CoorsTek, Evonik, JSR, Mitsubishi Chemical Holdings Corporation, Murata, Nitto Denko, SABIC, Samsung, Solvay, Toyota Tsusho, and Umicore.
Pangaea invests in start-up companies that use advanced materials to make our world better. Breakthroughs in advanced materials are becoming increasingly important for companies to excel in almost any market. Advanced materials are solving fundamental problems necessary to make products more efficient, sustainable, less expensive, and better performing, key attributes necessary for widespread adoption of any product. Pangaea’s current fund is focused on advanced materials within energy, electronics, health, and sustainability.
Pangaea is focused on achieving superior exits and returns for our investors, which drives a strong preference for capital efficient businesses. We like to hold significant minority stakes in companies and maintain those stakes over all stages of financing. It is important that the future capital requirements of any portfolio company be a fit for our fund.
Our investment thesis is technology- and IP-driven. Most high-multiple exits have been achieved by start-ups with a significant patent portfolio, offering excellent protection from competitors. This makes the acquisition target a very attractive growth platform for acquiring companies.
Of course, the strength of the entrepreneurs is critically important to our decision to invest, as well as to the success of the start-up. Pangaea’s portfolio boasts management teams coming from the highest levels of major multinationals as well as “Golden Touch” serial entrepreneurs.
With all this and more in mind, Pangaea is actively investing in companies using advanced materials to make our world better.

Name Fund: Clean Energy Venture Group / http://cevg.com/

Name Contact Visit: David Miller

Managing Director


Founder and Executive Managing Director of CEVG. An engineer by training, he brings over twenty years of technology startup management experience and over fifteen years of seed stage investing experience. He has been on the board of directors or advisory board of several clean energy companies, including Next Step Living, MyEnergy, Azima DLI, and Cambrian Innovation and has mentored many others. He also has an appointment as Research Affiliate at MIT’s Sloan School of Management.

David is a New England Chapter Director of Environmental Entrepreneurs (E2), a national community of business leaders who advocate for good environmental policy while building economic prosperity(www.e2.org) and has developed relationships with state and federal policy makers to support the growth of the clean energy industry. He is a founding member of the MIT Enterprise Forum’s Energy Special Interest Group and chaired the mentor program for what is now the Northeast Cleantech Open for its first four years. David also co-founded EPrime, which is a forum for clean energy entrepreneurs to network and support each other’s enterprises, was a board member of New England Energy and Environmental Funders, which educated investors interested in energy and environmental companies, and was a founding advisory board member of the New England Clean Energy Council.

Previously, David founded several companies, including Quantum Telecom Solutions which developed software for programmable switching equipment. He grew the company to profitability, with over 100% annual growth over a four-year period and then negotiated venture financing and sold the company to a division of Lucent Technologies. At Lucent, he served as Director in the New Ventures Group where he managed and evaluated a diverse set of early stage investments.



Formed in 2005, the Clean Energy Venture Group is composed of seasoned entrepreneurs, executives and investment professionals with deep experience in the areas of energy, environmental and sustainability.

CEVG partners believe that investing in clean energy and sustainable technologies and business execution models could provide very attractive risk-adjusted returns as well as contribute toward mitigating climate disruption. This serves as our strategic imperative for investments, which we typically make at the seed or early stage of a company’s evolution. Members provide hands-on management support and mentoring to our portfolio companies. With each investment, we not only bring capital, but also the value of our experience and network to help companies achieve their goals. We typically invest alongside other angel groups, individual investors and venture capital firms and take a collaborative approach to investing.

Our focus is New England, but we occasionally invest in companies located in other areas. To date, CEVG members have invested in over 20 clean energy companies, amounting to over 80 distinct rounds including follow-on investments. The group has had several successful exits. CEVG partners are deeply committed to and involved in the clean energy ecosystem in the Northeast and members serve on boards and as advisors to organizations promoting investment and policy changes in support of the clean energy and sustainability sectors.

Name Fund: Firelake Capital Management / http://firelakecapital.com/

Name Contact Visit: Peter Shannon

Managing Director


Peter Shannon  joined Firelake Capital Management as a Managing Director in 2010. He is focused on early stage investments in renewable energy, technologies improving use and delivery of natural resources, and other innovations on mature industries.

From 2005 until joining Firelake, Peter was a Principal at Atlas Venture, where he focused on solar, grid-scale energy storage, industrial energy efficiency, solid state data storage, and related software investments. Over his time at Atlas, he served as an observer on the boards of Advanced Electron Beams, Simple Tuition, MiaSolè, Songbird, Active Endpoints, Pixtronix, and Lilliputian Systems.

Before joining Atlas Venture, Peter was an MBA student at the University of Chicago Booth School of Business, and prior to that was Vice President of Technology at Browz Group, a company he invested in and advised throughout start-up. Browz Group provides large customers in power generation, chemical, mining, and other heavy industries with on-line supply chain verification services, to help them and their suppliers exchange compliance-related information.

Peter’s experience in software design and management in startups began while an undergraduate, when he co-founded Eye Response, Inc., a company that pioneered computer eye tracking systems. He authored a U.S. Patent and drove commercialization of the technology for applications in healthcare as communication aid for quadriplegics, as well as broader consumer applications as an augmentation to the computer mouse. Eye Response was acquired by DynaVox in 2009.

Peter holds an MBA, with High Honors, from the University Of Chicago Booth School Of Business and a BS, with Distinction, in Systems Engineering from the University of Virginia. He is a member of the boards of ArrayPower, Global Fresh Foods, QBotix and Sungevity and is a board observer of Novatorque.

Firelake Capital


While other firms look to invest in the tried-and-true, we seek out the disruptive. The ideas everyone else writes off as outrageous or impossible. The ones most venture capitalists would consider weird. We take the so-called wild and crazy ideas and develop them into intelligent, scalable solutions.
We are early-stage investors with a long-term investment horizon. We aim to solve our world’s most pressing problems through transformational, rather than incremental, change. That’s why we invest in areas where we believe new technologies or even an early-stage idea can significantly change the economics of current markets: areas like energy, water, material sciences, and global supply chains.


Contact: chilemass@incubatec.cl – Web designed by Incubatecufro.